Background RV144 is to date the only HIV vaccine trial to demonstrate efficacy, albeit rapidly waning over time. The HVTN 702 trial is currently evaluating in South Africa a similar vaccine formulation to that of RV144 for subtype C HIV with additional boosters (pox-protein regimen). Using a detailed stochastic individualbased network model of disease transmission calibrated to the HIV epidemic, we investigate population-level impact and maximum cost of an HIV vaccine to remain cost-effective.
first dose and include two-yearly boosters that maintain durable efficacy over 10 years. We simulate vaccination programs in South Africa starting in 2027 under various vaccine targeting and HIV treatment and prevention assumptions.
Results
Our analysis shows that this partially effective vaccine could prevent, at catchup vaccination with 60% coverage, up to 941,000 (15.6%) new infections between 2027 and 2047 assuming current trends of antiretroviral treatment. An impact of up to 697,000 (11.5%) infections prevented could be achieved by targeting age cohorts of highest incidence. Economic evaluation indicates that, if treatment scale-up was achieved, vaccination could be cost-effective at a total cost of less than $385 and $62 per 10-year series (cost-effectiveness thresholds of $5,691 and $750).
Conclusions
While a partially effective, rapidly waning vaccine could help to prevent HIV infections, it will not eliminate HIV as a public health priority in sub-Saharan Africa. Vaccination is expected to be most effective under targeted delivery to age groups of highest HIV incidence. Awaiting results of trial, the introduction of vaccination should go in parallel with continued innovation in HIV prevention, including studies to determine the costs of delivery and feasibility and further research into products with greater efficacy and durability.
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Introduction
With an estimated global prevalence of 36.7 million infected people as of 2015, HIV remains a public health priority in many countries [1] . Despite continued efforts to scale up treatment, resulting in 18.2 million people receiving antiretroviral therapy [2], an estimated 2.1 million people (including 150,000 5 children) were newly infected in 2015. Reaching the ambitious goal of 90-90-90 by 2020 (90% of people infected with HIV should know their status, with 90% of people diagnosed with HIV infection to be receiving antiretroviral treatment and 90% of people receiving treatment to have viral suppression) would not only diminish a substantial treatment gap but also prevent new infections. However, 10 a recent modeling study including 127 different countries suggests that the majority of countries under consideration (including South Africa) is unlikely to meet the 90-90-90 target [3] . This, and the difficulty in rolling out existing methods of HIV prevention (such as medical male circumcision, and oral preexposure prophylaxis) to key populations, highlight the need for a preventative 15 vaccine [4] .
October of 2016 marked the launch of the first trial in seven years to test the preventative efficacy of an HIV vaccine in humans. HVTN 702 is a phase 2b/3 trial [5], supported by the Pox-Protein Public-Private Partnership (P5) [6] . It 20 is testing a modified version of the only HIV vaccine to date that has shown evidence of efficacy in humans. In 2009, RV144 showed partial reduction in HIV acquisition among community-based, predominantly heterosexual participants in Thailand using a modified intent-to-treat analysis (vaccine efficacy of 31.2% (95% CI: 1.1% -52.1%) at month 42 after the first vaccination) [7] . Though 25 the efficacy of the vaccine appeared to be greatest shortly after the last dose and then waned rapidly, a recent follow-up study [8, 9] in which a subset of RV144 participants was re-vaccinated up to six years after enrollment reported immune memory responses two weeks after re-vaccination, offering hope that an extended immunization schedule could potentially increase vaccine durability. ule should account for any waning efficacy, recommendations for booster dose frequency, and rate of attrition from the recommended series of HIV vaccine doses. Second, a licensed vaccine may take up to a decade before being approved for widespread use in South Africa. In the interim, nationally representative HIV epidemiologic patterns are likely to change from current data, which dates back to 2012. Forecasting changes in incidence patterns is needed 75 to predict the likely impact of implementation scenarios under consideration and design a relevant and effective scale-up strategy. Finally, the patterns of HIV transmission must be accounted for in order to fully capture the potential population-level impact of a vaccine. Effective vaccination will prevent HIV infections not only in the direct recipients, but also in their sexual partners within 80 the contact network.
Several modeling studies [3, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24] have estimated impact and cost-effectiveness of an RV144-like vaccine, but all have assumed either a constant level of efficacy or exponentially waning immunity after 85 a single course of vaccination. In addition to bridging these gaps, the present work offers additional improvements such as application of an age-structured HIV network model, more realistic date of vaccine introduction, and complex booster schedules. Here, we estimate the impact of a 10-year vaccine regimen (primary series and boosters) within a 20-year vaccination program on the HIV 90 epidemic in South Africa using an individual-based network model of HIV transmission structured by age, sex and risk. We model the efficacy profile associated with the 5-dose regimen following the original HVTN 702 protocol and include possible booster doses following the primary series (beginning at 36 months from the first vaccination). The present analysis evaluates and compares the impact 95 and cost-effectiveness of implementation strategies initiating HIV vaccination based on targeted age groups, coverage goals, booster attrition, roll-out, HIV treatment scale-up, and oral pre-exposure prophylaxis (PrEP) availability.
Results from the present modelling analysis will help to inform ongoing vac-100 cine access planning elements, including priority populations for whom the poxprotein HIV vaccine would be expected to have the greatest and/or most efficient public health impact.
Methods
We developed an agent-based model of the South African population to 105 forecast HIV infections, disability-adjusted life-years (DALYs), and healthcare costs from a government payer perspective over a 30-year time horizon, from year 2018 to 2047. As compared to a reference case with no HIV vaccine, we evaluate implementation of strategies for initiation of HIV vaccination.
Model set-up and calibration. We modified EMOD-HIV v2.5, an age-stratified To ensure that our analysis reflected the realities of the HIV epidemic and the health system in South Africa, we iteratively engaged South African govern-120 ment, academic and community stakeholders through one-on-one interviews, a vaccine access planning summit and a public health impact modelling workshop during which preliminary results of this work were presented and discussed.
This stakeholder engagement process helped us understand perspectives on the future HIV prevention landscape, benefits of and challenges to reaching specific 125 target populations and the economic factors that will influence vaccine access, all of which were incorporated into our analysis and considerations. The parameters, model input values, sources, projections, and sensitivities of the epidemic projection without vaccine, used as the reference group for comparison, have been described previously [25, 26, 27] . A detailed model description, 130 user tutorials, model installer, and source code are available for download at http://idmod.org/software. 
where a i is the efficacy increase of immunization with ALVAC-HIV-C, b i is efficacy increase after ALVAC-HIV-C + gp120 immunization, ω is the efficacy decay rate per month and d is the delay between immunization and initiation (Table S1 ), and catch-up vaccination scenarios (Table S2) were implemented for individuals within a prespecified age range starting in 2027 with a linearly increasing coverage to reach 185 the ramp-up coverage in 2032, followed by cohort-like vaccination from 2032 onwards for individuals aging into the target range at a maintenance coverage which was 20% higher than the ramp-up coverage. For both roll-out scenarios, we assumed no coverage attrition for the primary immunization series. Eligibility for vaccination was assumed to be independent of PrEP usage, and Based on strategy-dependent changes in total discounted healthcare costs and DALYs, as compared to the reference with no vaccine, we estimated the maxi-245 Table 54 in [29] ). and discounted annually at a fixed rate of 0, 3 or 5%. The strategy-specific maximum vaccine cost that remains cost-effective was defined as the maximum regimen cost such that net DALY burden would remain negative, indicating a reduction in population burden of disease (i.e. health gain) from vaccine and 265 improvement in societal welfare. Bootstrapped confidence intervals for vaccine cost were obtained by the same method as described above in the section on population-level impact. 
Results

Incidence given no HIV vaccine
Time-dependent and cumulative vaccine efficacy
Impact of targeting and durability
To determine vaccination age-targeting of highest impact, we compare cohort vaccination at age 18 to age 15, with or without a 5-year age off-set between men and women ( Figure 3treatment and prevention scale-up scenarios (see Figure S3 for 50% coverage outcomes). Vaccine eligibility at 15 years of age with full booster retention for one decade prevents between 321, 000 (95% CI: 312, 000 − 329, 000) and 504, 000 (95% CI: 494, 000−516, 000) new infections over twenty years, assuming PrEP' scenario. High booster attrition at 50% would decrease these numbers to 176, 000 (95% CI: 168, 000 − 185, 000) and 309, 000 (95% CI: 296, 000 − 320, 000) respectively.
A difference in vaccination age between men and women of 5 years provides additional benefit with up to 402, 000 (95% CI: 392, 000 − 412, 000) and 642, 000 325 (95% CI: 632, 000 − 652, 000) of new infections prevented for the two scale-up scenarios respectively. Missing 50% of booster would decrease the impact to 256, 000 (95% CI: 247, 000 − 265, 000) and 434, 000 (95% CI: 426, 000 − 443, 000) for vaccination assuming 'Fast Track with PrEP' and 'Status Quo without PrEP' respectively.
330
Further impact can be achieved by targeting 18-year-olds resulting in 426, 000 (95% CI: 416, 000−435, 000) and 604, 000 (95% CI: 593, 000−615, 000) infections prevented respectively at 0% booster attrition. Echoing the age difference in the peak of HIV incidence, vaccinating 18-year-old women and 23-year-old men 335 would increase the impact to up to 501, 000 (95% CI: 491, 000 − 512, 000) and 697, 000 (95% CI: 687, 000 − 707, 000) infections prevented respectively, given full booster retention.
The impact of age off-setting and vaccination age is also highlighted by the Catch-up vaccination appears to be particularly impactful, i.e. by targeting 350 age ranges between 15 to 32 at the beginning of the roll-out at 60% coverage and maintaining cohort coverage of 80% thereafter, the number of new infections prevented increases from 321, 000 to 689, 000 (95%CI: 679, 000−699, 000) (or 18.1% (95%CI:17.9−18.3%)) and from 504, 000 to 941, 000 (95%CI: 932, 000−951, 000) (or 15.6% (95%CI: 15.5 − 15.7%)) for 'Fast Track with PrEP' and 'Status Quo 355 without PrEP' scenarios respectively ( Figure S4 ). Shifting the age range for catch-up vaccination to 18 to 35 years would have a similar impact of 695, 000 (95%CI: 686, 000 − 704, 000) (or 18.3% (95%CI: 18.1 − 18.5%)) and 935, 000 (95%CI: 924, 000 − 945, 000) (or 15.5% (95%CI: 15.3 − 15.6%)) infections prevented respectively. Quo without PrEP' scenario ( Figure S8 ).
Discussion
The results of this study highlight the need to exploit different vaccination targeting and roll-out scenarios to maximize the population-level impact of a 405 partially effective HIV vaccine in South Africa. Even under high attrition rates, providing additional booster doses for up to one decade after the primary series can increase public health impact, as long as gender-specific age ranges of highest incidence are covered by vaccination. Although adolescent HIV vaccination has the potential of reaching high coverage in South Africa through school-410 based programs (such as Human Papilloma Virus routine vaccination [45] ), our modeling results (see Table 2 and Table S3 ) do not make a strong case for vaccinating before the age of sexual debut, estimated at a median of 18 years of age [46] . The same conclusion applies to the potential impact on vertical transmission by vaccinating 15-year-old women. Prevention of mother-to-child 415 transmission is efficacious in South Africa (only 1.3 % of live births in 2017 were HIV positive [47] ) and only 12% of live births are given at age 19 or younger whereas 70% of births are given at ages 20-34 [48] .
The time-dependent course of vaccine efficacy necessitates aligning vaccination such that the times of highest efficacy are within the ages of highest HIV 420 incidence in 2027 -projected to be 20-25 years of age for women, and five to ten years older for men ( Figure S9 ). Specifically, our results indicate that, of the gender/age combinations we compared, the greatest public health impact of the pox-protein HIV vaccine would be achieved by vaccinating 18-year-old women and 23-year-old men. such as staff training, information campaigns and monitoring for such a complex regimen made it challenging to carry out a well-informed cost breakdown analysis. Furthermore, different target populations may be more or less challenging to reach. This is difficult to know a priori and was not included in the analysis, 475 and therefore remains an area important to explore in close collaboration with implementers of HIV prevention programs. We did not model risk compensation [15, 51] i.e. increases in risky behavior by vaccine recipients, bearing in mind that a partially effective vaccine might necessitate additional counseling to prevent the false impression of full protection. Vaccine-induced seropositivity 
Conclusion
Taken together, our model suggests that, averaged across different treatment scale-up settings, vaccinating population cohorts aligned with the ages of highest HIV incidence (i.e. 18-year-old women and 23-year-old men) including 490 continued boosting for up to 10 years could avert up to 13.1% and 11.5% of HIV infections in the coming decades (for 'Fast Track with PrEP' and 'Status Quo without PrEP' respectively). If durability of vaccine efficacy proves to be better than observed in the RV144 trial, the benefit could be appreciably larger. Adult catch-up vaccination and efforts to ensure continued boosting, 495 could further increase the impact of the vaccination to possibly just over 18.3% (or 694, 000) and 15.5% (or 935, 000) of new infections prevented (for 'Fast Track with PrEP' and 'Status Quo without PrEP' respectively). However, we recognize that identifying optimal vaccine implementation platforms and deployment channels to deliver this complex vaccine regimen at high coverage 
